Delayed Contrast Extravasation MRI for Depicting Tumor and Non-Tumoral Tissues in Primary and Metastatic Brain Tumors

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Zach, Leor ^a,b   Guez, David ^a   Last, David ^a   Daniels, Dianne ^a,b   Grober, Yuval ^a   Nissim, Ouzi ^a   Hoffmann, Chen ^a,b   Nass, Dvora ^a   Talianski, Alisa ^a   Spiegelmann, Roberto ^a,b   Cohen, Zvi R ^a,b   Mardor, Yael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERATE MEGLUMINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURGERY; CANCER TISSUE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED CONTRAST EXTRAVASATION NUCLEAR MAGNETIC RESONANCE IMAGING; FEMALE; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; STEREOTACTIC BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84871278465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052008     Document Type: Article

References (55)

1. Fink J, Born D, Chamberlain MC, (2011) Pseudoprogression: Relevance with respect to treatment of high-grade gliomas. Curr Treat Opt in Oncol 12: 240-252.
2. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ, (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9: 453-461.
3. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE, (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82: 81-83.
4. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, et al. (2008) Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113: 405-410.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
6. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ, (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63: 535-537.
7. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H, (2009) Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72: 423-428.
8. Brandsma D, van den Bent MJ, (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22: 633-638.
9. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, et al. (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma, Neurology. 76: 1918-1924.
10. Jahangiri A, Aghi MK, (2012) Pseudoprogression and treatment effect. Neurosurg Clin N Am 23: 277-287.
11. Rane N, Quaghebeur G, (2012) CNS effects following the treatment of malignancy. Clin Radiol 67: 61-68.
12. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol. 28: 1963-1972.
13. Van den Bent M, Volgelbaum M, Wen P, Macdonald DR, Chang SM, (2009) Endpoint assessment in gliomas: novel treatments limit the usefulness of the classical Macdonald criteria. J Clin Oncol 27: 2905-2908.
14. Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, et al. (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82: 436-444.
15. Perry A, Schmidt RE, (2006) Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 111: 197-212.
16. Kim JH, Bae Kim Y, Han JH, Cho KG, Kim SH, et al. (2012) Pathologic Diagnosis of Recurrent Glioblastoma: Morphologic, Immunohistochemical, and Molecular Analysis of 20 Paired Cases. Am J Surg Pathol 36: 620-628.
17. Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, et al. (2012) Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol May 17 [Epub ahead of print].
18. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, et al. (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 37: 272-282.
19. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, et al. (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47: 291-298.
20. Rock JP, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, et al. (2004) Associations among MRS, ADC, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54: 1111-1117.
21. Chan YL, Yeung DK, Leung SF, Chan PN, (2003) DWMRI in radiation-induced cerebral necrosis. ADC in lesion components. J Comput Assist Tomogr 27: 674-680.
22. Zeng QS, Li CF, Zhang K, Liu H, Kang XS, et al. (2007) Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 84: 63-69.
23. Stadnik TW, Chaskis C, Michotte A, Shabana WM, van Rompaey K, et al. (2001) Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 22: 969-976.
24. Lu S, Ahn D, Johnson G, Law M, Zagzag D, et al. (2004) Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema. Radiology 232: 221-228.
25. Matsusue E, Fink JR, Rockhill JK, Ogawa T, Maravilla KR, et al. (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52: 297-306.
26. Xu JL, Li YL, Lian JM, Dou SW, Yan FS, et al. (2010) Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging. Neuradiology 52: 1193-1199.
27. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, et al. (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of PET? Am J Neuroradiol 19: 407-413.
28. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, et al. (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-in malignant glioma. Ann Nucl Med 18: 291-296.
29. Nelson SJ, (2011) Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed 24: 734-749.
30. Lacerda S, Law M, (2009) Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 19: 527-557.
31. Mills SJ, Soh C, O'Connor JP, Rose CJ, Buonaccorsi G, et al. (2010) Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: a dynamic contrast-enhanced MR imaging study. Am J Neuroradiol 31: 726-731.
32. Barboriak DP, MacFall JR, Viglianti BL, Dewhirst MW, (2008) Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging 27: 1388-1398.
33. Aronen HJ, Perkiö J, (2002) Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 12: 501-523.
34. Covarrubias DJ, Rosen BR, Lev MH, (2004) Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 9: 528-537.
35. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, et al. (2000) Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast- enhanced MRI for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. Am J Neuroradiol 21: 901-909.
36. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, et al. (2009) Relative cerebral blood volume values to differentiate highgrade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR 30: 552-558.
37. Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, et al. (2009) Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 250: 887-896.
38. Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, et al. (2010) Changes in relative cerebral blood volume 1 month after radiation temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 256: 575-584.
39. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, et al. (2010) Differentiating radiation necrosis from tumor recurrence in highgrade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 112: 758-765.
40. Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, et al. (2011) Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced Magnetic resonance imaging using ferumoxytol vs gadoteridol: A pilot study. Int J Radiat Oncol Biol Phys 79: 514-523.
41. Narang J, Jain R, Arbab AS, Mikkelsen T, Scarpace L, et al. (2011) Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion, Neuro-Oncol. 13: 1037-1046.
42. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, et al. (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility weighted contrast-enhanced perfusion MR imaging. Radiology 253: 486-496.
43. Hazle JD, Jackson EF, Schomer DF, Leeds NE, (1997) Dynamic imaging of intracranial lesions using FSE imaging: differentiation of brain tumors and treatment effects. J Magn Reson Imaging 7: 1084-93.
44. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, et al. (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105: 5213-5238.
45. Israeli D, Tanne D, Daniels D, Last D, Shneor R, et al. (2011) The Application of MRI for Depiction of Subtle Blood Brain Barrier Disruption in Stroke. Int J Biol Sc 7: 1-8.
46. Peto R, Peto J, (1972) Asymptotically efficient rank invariant test procedures. J Roy Stat Soc Series A 135: 195-206.
47. Moses L, (1952) Non-parametric statistics for psychological research. Psychol Bull 49: 122-143.
48. Rane N, Quaghebeur G, (2012) CNS effects following the treatment of malignancy. Clin Radiol 67: 61-68.
49. Abe E, Aoyama H, (2012) The role of whole brain radiation therapy for the management of brain metastases in the era of stereotactic radiosurgery. Curr Oncol Rep 14: 79-84.
50. Tonn JC, Thon N, Schnell O, Kreth FW, (2012) Personalized surgical therapy. Ann Oncol 23Suppl 10: x28-x32.
51. Russell SM, Elliott R, Forshaw D, Golfinos JG, Nelson PK, et al. (2009) Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol 72: 242-246.
52. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
53. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, et al. (2009) Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 29: 853-860.
54. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259.
55. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, et al. (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-oncol 13: 307-316.